2023 年 3 月 16 日，YS Biopharma 与 Summit Healthcare 合并。 此前，该公司未能披露Summit 从成立起就打算与 YS Biopharma 或 Yishengbio 合并，后者是一家处于亏损状态的劣质中国生物制药公司，损害了Summit 公众股东的利益。
本消息导致 YS Biopharma 股价在 2023 年 3 月 17 日下跌 每股 2.6 美元或 20%，收于每股 10.14 美元。
NASDAQ: YS, SMIH
YS Biopharma Co., Ltd.
罗森律师事务所宣布一项代表YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. (NASDAQ: YS, SMIH) 的投资人对该公司潜在的集体诉讼请求发起调查。该调查缘起于对YS Biopharma 可能向投资公众发布了具有重大误导性的商业信息的指控。
如果您购买了YS Biopharma股票，并且您想参加此次集体诉讼的话，请点击“加入此集体行动”键。
如果您购买了 YS Biopharma证券，您可能有权获得赔偿，而无需支付任何自付费用或通过应急费用安排产生的费用。
Company Name:
YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp.
Stock Symbol:
YS, SMIH
Class Period:
N/A
Court:
N/A
Why Rosen Law
The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.
Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.
Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.
The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.
